In the Journals

Cancer survivors at higher medium-, long-term risk for cardiovascular disease

August 23, 2019
Survivors of most types of cancers demonstrated increased medium- to long-term risk for at least one cardiovascular disease compared with the general…

FDA grants priority review to zanubrutinib for relapsed/refractory mantle cell lymphoma

August 22, 2019
The FDA granted priority review to zanubrutinib for the treatment of patients with relapsed or refractory mantle cell lymphoma, the drug’s…

Feature

‘Smarter and stronger’ T cells offer hope for more effective, less toxic cancer therapy

August 18, 2019
Editor’s note: This is the first in a series of articles that spotlight research efforts supported through Cancer Research Institute’s…

In the Journals

CAR T-cell therapy shows activity in lymphoma despite lack of measurable disease

August 14, 2019
Tisagenlecleucel showed measurable in vivo expansion in patients with relapsed or refractory diffuse large B-cell lymphoma who had no measurable…

In the Journals

OS rate for Hodgkin lymphoma remains high with PET response-adapted therapy

August 13, 2019
Patients with advanced, persistent Hodgkin lymphoma who switched to an escalated treatment regimen as part of a PET-adapted therapy approach achieved…

Feature

Surgery may benefit certain patients with primary central nervous system lymphoma

August 13, 2019
Cytoreductive surgery may be an effective treatment option for specific subgroups of patients with primary central nervous system lymphoma, according…

In the Journals

Antibiotics thwart disease activity in advanced cutaneous T-cell lymphoma

August 11, 2019
Antibiotics administered to treat Staphylococcus aureus appeared to inhibit disease activity among patients with advanced cutaneous T-cell lymphoma…

Trend Watch

CAR T-cell therapy made available to all Medicare recipients

August 8, 2019
On Wednesday, the Trump Administration made chimeric antigen receptor T-cell therapy available to all Medicare beneficiaries via a long-awaited final…

In the Journals

Rituximab maintenance confers lasting PFS benefit for patients with follicular lymphoma

August 6, 2019
Rituximab maintenance following induction immunochemotherapy conferred durable PFS compared with observation among patients with follicular lymphoma…

Trend Watch

CMS increases CAR T reimbursement by 15%

August 5, 2019
CMS has finalized its plan to increase its new technology add-on payment to 65% of the total cost of chimeric antigen T-cell therapies. The payment…

In the Journals

BRCA2 mutation may predispose children to lymphoma

July 25, 2019
Inherited heterozygous BRCA2 mutations appeared to increase risk for non-Hodgkin lymphoma in children and adolescents, according to a research…

Trend Watch

New Trial Uses Bispecific CAR T-Cell Therapy to Target Pediatric ALL

Cell Therapy Next, July 2019
Children’s National Health System in Washington, D.C., announced that it will be the second location to enroll patients in a pediatric trial…

In the JournalsPerspective

Neurotoxicity Affects Nearly Half of Patients Receiving CAR T-cell Therapy

Cell Therapy Next, July 2019
New data revealed that 48% of patients who received chimeric antigen receptor T-cell therapy for cancer treatment experienced neurological toxicity…

FDA NewsPerspective

At FDA’s request, Allergan recalls breast implants linked to rare lymphoma

July 24, 2019
In response to a request from FDA, Allergan recalled specific models of its textured breast implants due to a potential risk for breast…

Foundation to present leadership award to Memorial Sloan Kettering lymphoma specialist

July 24, 2019
The Lymphoma Research Foundation will present its Distinguished Leadership Award to Anas Younes, MD, at its annual gala on Sept. 26. Younes —…

FDA News

FDA approves Ruxience, biosimilar to Rituxan, for blood cancers, autoimmune conditions

July 23, 2019
The FDA approved rituximab-pvvr, a biosimilar to rituximab, for multiple indications. Rituximab-pvvr (Ruxience, Pfizer) is the second biosimilar to…

In the JournalsPerspective

CAR T-cell therapies may be cost-effective for patients with lymphoma subtype

July 23, 2019
The chimeric antigen receptor T-cell therapies axicabtagene ciloleucel and tisagenlecleucel may meet a cost-effectiveness threshold of less than…

In the Journals

CD19-specific CAR T-cell therapy feasible for aggressive non-Hodgkin lymphoma

July 23, 2019
CD19-specific chimeric antigen receptor T-cell therapy after high-dose chemotherapy and autologous stem cell transplant appeared feasible for…

Seven important updates in immuno-oncology

July 19, 2019
Healio.com and HemOnc Today provide a compilation of seven important updates in immuno-oncology from the past month.

In the JournalsPerspective

PD-L1 alterations identify T-cell inflamed diffuse large B-cell lymphoma

July 17, 2019
PD-L1 alterations appeared to identify a subset of patients with diffuse large B-cell lymphoma who have an endogenous anti-lymphoma immune response…